SG11202002731YA - Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one - Google Patents

Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

Info

Publication number
SG11202002731YA
SG11202002731YA SG11202002731YA SG11202002731YA SG11202002731YA SG 11202002731Y A SG11202002731Y A SG 11202002731YA SG 11202002731Y A SG11202002731Y A SG 11202002731YA SG 11202002731Y A SG11202002731Y A SG 11202002731YA SG 11202002731Y A SG11202002731Y A SG 11202002731YA
Authority
SG
Singapore
Prior art keywords
difluorophenethyl
undecan
diazaspiro
oxa
salts
Prior art date
Application number
SG11202002731YA
Inventor
Carmen Almansa-Rosales
Nicolas Tesson
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of SG11202002731YA publication Critical patent/SG11202002731YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202002731YA 2017-10-17 2018-10-16 Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one SG11202002731YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382695 2017-10-17
PCT/EP2018/000470 WO2019076475A1 (en) 2017-10-17 2018-10-16 Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

Publications (1)

Publication Number Publication Date
SG11202002731YA true SG11202002731YA (en) 2020-05-28

Family

ID=60201976

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002731YA SG11202002731YA (en) 2017-10-17 2018-10-16 Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

Country Status (21)

Country Link
US (1) US11236110B2 (en)
EP (1) EP3697795B1 (en)
JP (1) JP2020537648A (en)
KR (1) KR20200071107A (en)
CN (1) CN111263764A (en)
AR (1) AR113770A1 (en)
AU (1) AU2018353107B2 (en)
BR (1) BR112020007359A2 (en)
CA (1) CA3076765A1 (en)
CO (1) CO2020005710A2 (en)
DK (1) DK3697795T3 (en)
FI (1) FI3697795T3 (en)
IL (1) IL273751B2 (en)
LT (1) LT3697795T (en)
MA (1) MA50395A (en)
MX (1) MX2020004214A (en)
PH (1) PH12020550104A1 (en)
PT (1) PT3697795T (en)
RU (1) RU2020115274A (en)
SG (1) SG11202002731YA (en)
WO (1) WO2019076475A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021018824A1 (en) * 2019-07-31 2021-02-04 Esteve Pharmaceuticals, S.A. Use of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one for the treatment of nociceptive pain, neuropathic pain, osteoarthritis pain and cancer pain, while having reduced side effects compared to opioids
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
DE102005030051A1 (en) 2005-06-27 2006-12-28 Grünenthal GmbH New substituted 1-oxo-3,8-diazospiro(4.5)-decan-2-one compounds are 5-hydroxy tryptamine uptake receptor inhibitors, useful to treat and/or prevent e.g. pain, migraine, chronic paroxysomal hemicrania, depression and asthma
US8168783B2 (en) 2005-11-18 2012-05-01 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
ES2541133T3 (en) 2007-03-01 2015-07-16 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
UA100400C2 (en) 2008-02-06 2012-12-25 Астразенека Аб Spirocyclic amide derivatives
ES2618929T3 (en) 2011-03-14 2017-06-22 Vertex Pharmaceuticals Incorporated Morpholine-Spiro piperidine cyclic amide as ion channel modulators
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
TN2015000474A1 (en) * 2013-04-23 2017-04-06 Esteve Labor Dr PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP2017100951A (en) * 2014-04-04 2017-06-08 大正製薬株式会社 Oxazolidinone and oxazinanone derivative
TW201615643A (en) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
TW201615642A (en) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
TWI685497B (en) 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain

Also Published As

Publication number Publication date
IL273751B1 (en) 2023-10-01
RU2020115274A3 (en) 2022-04-29
DK3697795T3 (en) 2024-02-26
US20200331929A1 (en) 2020-10-22
LT3697795T (en) 2024-04-10
CN111263764A (en) 2020-06-09
AU2018353107B2 (en) 2023-07-06
KR20200071107A (en) 2020-06-18
JP2020537648A (en) 2020-12-24
FI3697795T3 (en) 2024-02-23
RU2020115274A (en) 2021-11-01
EP3697795B1 (en) 2023-11-22
IL273751A (en) 2020-05-31
AU2018353107A1 (en) 2020-04-23
EP3697795A1 (en) 2020-08-26
PH12020550104A1 (en) 2021-01-25
AR113770A1 (en) 2020-06-10
WO2019076475A1 (en) 2019-04-25
PT3697795T (en) 2024-02-29
CO2020005710A2 (en) 2020-05-29
MX2020004214A (en) 2020-08-13
BR112020007359A2 (en) 2020-09-29
TW201922752A (en) 2019-06-16
MA50395A (en) 2020-08-26
US11236110B2 (en) 2022-02-01
IL273751B2 (en) 2024-02-01
CA3076765A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
IL276802A (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
EP3661918A4 (en) 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d]pyrimidin -3 - one analogs
AU2018258581A8 (en) RAF-degrading conjugate compounds
IL282178A (en) Products, uses & methods
EP3452481A4 (en) SUBSTITUTED IMIDAZO[1,2-b
EP4219526A3 (en) Method for preparing amg 416
IL260488B (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EP3660019C0 (en) 7h-pyrazolo[3,4-d]triazine-2-oxides as explosives
EP3846791A4 (en) Illudin analogs, uses thereof, and methods for synthesizing the same
EP3421444A4 (en) 1-chloro-2,3,3,3-tetrafluoropropene manufacturing method
IL273751A (en) Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
GB2577981B (en) Methods, products & Uses relating thereto
IL285204A (en) Afabicin formulation, method for making the same
GB201813648D0 (en) Methods, products & uses relating thereto
EP3222703B8 (en) Tealight cups, tealights and methods for the production thereof
EP3638220A4 (en) Process for the preparation of (s,s
WO2016145111A3 (en) Methods, systems and kits for enhanced muscle contractile capabilities
GB201817509D0 (en) Products, uses & methods
GB201816700D0 (en) Products, uses & methods
EP3876894A4 (en) Tether
GB201813647D0 (en) Methods, products & uses relating thereto
GB201815628D0 (en) Belisha beacon
GB201709607D0 (en) The P.I.R. Co. Ltd - business method patent
AU2018901799A0 (en) New synthetic methods
GB201715900D0 (en) Palate-transducers & palate-loudspeakers, new drawings